SHINE Plant Manager, Bill Hennessy (left), with CEO and Founder, Dr. Greg Piefer (right), testifying before the Nuclear Regulatory Commission at SHINE’s mandatory hearing in December 2015
Hospitals in the United States are constantly in shortage of radioactive elements used to diagnose and fight cancer and cardiovascular diseases. For the first time in over fifty years a company has received permit from the U.S. Nuclear Regulatory Commission to build a facility (in Janesville, Wisconsin) that will produce molybdenum-99, the most commonly used element that breaks down into technetium-99m for use in clinical applications.
This publication not being staffed by physicists, it’s not clear what production method will be used. But it will not be a nuclear reactor, like in the past. We’ve covered SHINE’s partnership with Argonne on new reactorless medical isotope production and the related work from the University of Wisconsin.
Product page: SHINE Medical…
Flashbacks: Argonne and SHINE Medical Show Off New Way of Producing Medical Isotope Mo-99… ; U of Wisconsin to Build Reactorless Mo-99 Medical Isotope Generation Facility…